Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
STLE Annual MeetingSTLE Annual Meeting
Not Confirmed
Not Confirmed
18-22 May, 2025
Not Confirmed
Not Confirmed
19-22 May, 2025
Not Confirmed
Not Confirmed
20-22 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
STLE Annual MeetingSTLE Annual Meeting
Industry Trade Show
Not Confirmed
18-22 May, 2025
Industry Trade Show
Not Confirmed
19-22 May, 2025
Industry Trade Show
Not Confirmed
20-22 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions
26 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sapience-therapeutics-to-present-multiple-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025-302411365.html
27 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-st316-phase-1-dose-escalation-data-at-the-2025-american-society-of-clinical-oncology-asco-gastrointestinal-gi-cancers-symposium-302360732.html
19 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sapience-therapeutics-receives-fda-orphan-drug-designation-for-st316-a-first-in-class--catenin-antagonist-for-the-treatment-of-familial-adenomatous-polyposis-fap-302335639.html
08 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-multiple-presentations-at-the-society-for-immunotherapy-of-cancers-sitc-39th-annual-meeting-302269680.html
01 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sapience-therapeutics-enrolls-first-patient-in-phase-2-study-of-st316-a-first-in-class--catenin-antagonist-in-colorectal-cancer-302263343.html
01 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-positive-clinical-and-biomarker-data-from-st101-phase-2-study-in-gbm-at-asco-2024-in-oral-presentation-302161146.html
ABOUT THIS PAGE